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disc and causes acute, unilateral, painless visual loss. There is no generally accepted treatment method for this condition but some
medical and surgical treatments are recommended. Earlier studies show that visual acuity recovery was better with corticosteroid
medication compared to non-treated patients. However corticosteroids may cause side effects such as cataract, increased intra-
ocular pressure and rarely central serous chorioretinopathy. This case report presents a patient with central serous chorioretinop-
athy secondary to corticosteroid medication.
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Corticosteroid medication for treatment of non-arteritic
anterior ischemic optic neuropathy is controversial. It may
cause a central serous chorioretinopathy (CSCR) and threaten
the patients’ visual acuity. As a treatment cutting of the cor-
ticosteroid medication should be advised. This case reports a
54-year-old male with CSCR secondary to corticosteroid
medication which is used for treating patients’ non-arteritic
anterior ischemic optic neuropathy (NAION). The corticoste-
roid treatment induced central serous chorioretinopathy in
patients’ healthy eye and reduced visual acuity.1–4 The corti-
costeroid treatment was stopped. Two months after that
visual acuity turned back to normal and central serous chori-
oretinopathy disappeared.
Case report
A 54-year-old male was referred to us with decreased
visual acuity in his right eye (RE). The best-corrected visualacuity (BCVA) was 0.05 in RE and 0.8 in left eye (LE). Ocular
history was unremarkable. The patient had a systemic hyper-
tension which was under control medically. Slit lamp examin-
ations of anterior segment were normal in both eyes.
Intraocular pressure (IOP) measurements were performed
via Goldmann applanation tonometer and IOP was 14 mmHg
in RE, 13 mmHg in LE. Relative afferent pupillary defect was
present in RE. Dilated fundus examination revealed splinter
hemorrhages and edema at the optic discs in RE. Fundus
examination was normal in LE. Perimetry was performed via
Humphrey 30–2 threshold test and there was a lower altitudi-
nal visual field defect in RE. Fundus fluorescein angiography
(FA) showed hyperfluorescence at the optic disc in RE and
normal angiographic findings in LE (Fig. 1a and b). Optic disc
appearance, visual fields, FA and optical coherence tomogra-
phy of discs were suggestive of non-arteritic anterior ischemic
optic neuropathy (NA-NAION) in RE. Patient was diagnosed
with NA-AION and methylprednisolone was administered
with a dose of 1 gr/day intravenously for 3 days. Then, steroid
treatment continued with 1 mg/kg/day orally for a week.e:
al.com
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patient complained decreased visual acuity in his LE. BCVA
was 0.05 in RE and 0.1 in LE. Relative afferent pupillary
defect was still present in RE. Anterior segment and IOP
measurements were normal in both eyes. Fundus examina-
tion showed decreased edema at the optic disc in RE.
Additionally, there was an elevation in the macula in LE.
Late-phase FA demonstrated granular hyperfluorescence
just located nasally to the fovea surrounded by serous
detachment in LE in addition to decreased hyperfluores-
cence at the optic disc in RE (Fig. 2a and b). Indocyanine
green angiography (ICG) showed focal hyperfluorescence
in mid-phase at the same location as in FA in LE (Fig. 2c).
Spectral-domain optical coherence tomography revealed
subretinal fluid in the macula in LE (Fig. 3). Central macular
thickness (CMT) was 610 lm. The patient was diagnosed
with acute CSC.
After the patient diagnosed steroid-induced CSCR, cor-
ticosteroid treatment was stopped abruptly. One month
later, BCVA was 0.5 in LE. CMT was decreased to
414 lm in LE. Two months after the cessation of corticoste-
roid treatment, BCVA improved to 0.8 in LE and 0.1 in RE.
There was no subretinal fluid and CMT was 279 lm in LE
(Fig. 4).Figure 2. Fundus fluorescein angiography scans showed decreased hyperfluo
chorioretinopathy in LE (b). Arrow indicates the border of the pigment epithe
green angiography scans showed focal hyperfluorescence coherent to fundus
Figure 1. Fundus fluorescein angiogram of both eyes (a, b). A hyperfluorescen
(b).Discussion
Central serous chorioretinopathy is characterized by ser-
ous detachment of the neurosensory retina due to defect in
the retinal pigment epithelium.1,2 CSCR most commonly
affects males between 20 and 50 years. Early studies showed
that CSCR is related to psychological stress, endogenous
hypercortisolism and use of corticosteroid medicines.3 It
has been shown that corticosteroid treatment given through
various routes such as oral, inhaled, epidural, intra-articular
may cause CSCR.4 Exact mechanism for steroid induced
CSCR has not been fully understood yet; however, it may
result from inhibition of collagen synthase, increasing perme-
ability of choroidal capillary, and dysfunction of ionic pump in
the retina pigment epithelium.5,6
Earlier studies showed that many CSCR may resolve
spontaneously and just observational therapy was needed
for 3–4 months.7 Some of CSCR cases may resolve with the
successful treatment of underlying pathology or mechanism.8
Vayalambrone et al. reported a 32-year-old Afro-Caribbean
male patients with multi-focal CSCR secondary to latent
tuberculosis. After the empiric antituberculous therapy, the
patient had a significant visual improvement with resolution
of the serous detachment.8 Similarly, in our patient afterrescence at the inferior half of the optic disc in RE (a) and a central serous
lial detachment and star indicates hyperfluorescence spots. Indocyanine
fluorescein angiography scan in LE (4c).
ce at the inferior half of the optic disc in RE (a) and normal angiogram in LE
Figure 3. Spectral domain optical coherence tomography shows serous
macular detachment as hyporeflective space between neurosensory
retina and RPE in LE.
Figure 4. Spectral-domain optical coherence tomography scans two
months after the corticosteroid treatment were stopped. The CSCR was
resolved.
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used, CSCR was resolved. After two months from stopping
corticosteroid treatment visual acuity backed to 0.8 in LE,
which was the same with patient’s previous visual acuity.
There were similar results reported in the literature.9,10
Shah et al reported a 24 year-old male with CSCR secondary
to prednisolone (60 mg/day) for treating left sided facial
palsy.9 The dose of prednisolone was reduced to 40 mg
and used for seven days then stopped.9 They reported thatvisual disturbances abated gradually within one week after
prednisolone was withdrawn.9 Loo et al. reported 3 patients
with CSCR secondary to corticosteroid medication for differ-
ent diseases.10 They reported that two of those cases
resolved with tapering of corticosteroids and one case was
treated by focal laser photocoagulation.10 There are still
some CSCR cases may not improve on conventional observa-
tional approach. Photodynamic therapy may be used for
these cases.11 Shibata et al. used photodynamic therapy for
treating two patients with CSCR and they reported that suc-
cessful results were achieved.11
There are new approaches for the treatment of NAION
such as local steroid application.12 As systemic steroid might
trigger CSCR in the fellow healthy eye as presented, local
(intravitreal) steroid application for the diseased eye would
have been more appropriate.12
Conclusion
This case showed that systemic corticosteroid treatment
may cause visual acuity loss due to CSCR and stopping the
corticosteroid administration may be appropriate treatment.
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